This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Trimeris Reports Financial Results For The Third Quarter 2010

Trimeris, Inc., (Nasdaq: TRMS) or the “Company,” today announced financial results for the quarter ended September 30, 2010, reporting net income of $16.5 million, or $0.74 per share compared with $1.6 million, or $0.07 per share for the quarter ended September 30, 2009. Comparisons of net income between the quarters ended September 30, 2010 and September 30, 2009 are affected by several items detailed in the section below entitled “Adjusted (Non-GAAP) Financial Information.” Excluding these items, the Company would have reported adjusted net income of $2.1 million or $0.10 per share in the third quarter of 2010.

For the nine months ended September 30, 2010, the Company reported net income of $18.8 million, or $0.84 per share, compared with $5.1 million, or $0.23 per share for the nine months ended September 30, 2009. Comparisons of net income between the periods are affected by several items detailed in the section below entitled “Adjusted (Non-GAAP) Financial Information.” Excluding these items, the Company would have reported adjusted net income of $2.4 million, or $0.11 per share for the nine months ended September 30, 2010, compared with $4.5 million, or $0.20 per share for the nine months ended September 30, 2009.

Collaboration income for the quarter ended September 30, 2010 was $20.0 million compared with $1.7 million for the quarter ended September 30, 2009. This increase was primarily driven by the Company’s agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”) in September 2010 (see “Deferred Marketing Expenses” discussion below), which relieved Trimeris of any obligation to repay certain deferred marketing expenses to Roche in the amount of $18.7 million and a decrease in selling and marketing expenses offset, in part, by payments under the settlement agreement with Novartis, and a decrease in net sales of FUZEON in the U.S. and Canada. Net sales of FUZEON in the U.S. and Canada for the third quarter of 2010 were $9.0 million, down 14 percent from $10.4 million in the third quarter of 2009.

1 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs